GlassScriptPhysician profile
Robert J Maydell
NPI 1851547327
$1,341.40
in general payments reported to CMS, 2019-2025
19 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $68.16 · 2021: $80.78 · 2022: $162 · 2023: $199 · 2024: $462 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.89 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $170.36 | 2021-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $148.80 | 2021-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $133.96 | 2020-2025 | Rexulti |
| Axsome Therapeutics, INC. | $125.48 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $94.83 | 2022-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $85.77 | 2020-2023 | Uzedy |
| Almatica Pharma LLC | $79.54 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Alkermes, INC. | $67.59 | 2024-2025 | Lybalvi |
| Corium, LLC | $48.83 | 2025 | Azstarys |
| Bausch Health US, LLC | $30.63 | 2024 | Wellbutrin, Aplenzin |
| Collegium Pharmaceutical, INC. | $30.19 | 2025 | Jornay Pm |
| Lundbeck LLC | $22.88 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $22.30 | 2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $20.16 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $19.58 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.75 | 2021 | |
| Neos Therapeutics, LP | $16.31 | 2025 | Adzenys Xr-Odt |
| Kls-Martin L.P. | $9.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Maydell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.